Tag Archive for: ublituximab

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

/in

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil® (modafinil), and bring BRIUMVI® (ublituximab) to patients in Australia  Sydney, Australia and Düsseldorf, Germany – 22 July 2025 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on […]

Read more

NICE Recommends ublituximab (BRIUMVI®▼) as an Option for Treating Relapsing-Remitting Multiple Sclerosis (RRMS)

/in

London, UK, Barcelona, Spain and Düsseldorf, Germany – 5 December 2024 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces that the National Institute for Health and Care Excellence (NICE) in the UK has issued a positive recommendation for the use of ublituximab (150 mg concentrate […]

Read more